How Genetics Work in Diagnosing Lewy Body Dementia

See which genes raise Lewy body dementia risk and which practical steps help families respond.

Genetics play a supporting role in diagnosing Lewy body dementia, not a deciding role. Doctors do not use gene tests to make the diagnosis; they use thinking changes, movement and sleep symptoms, and brain imaging, while genes only signal risk. Lewy body dementia (LBD) means dementia caused by Lewy bodies, clumps of protein that build up in brain cells. As noted in a risk overview from For Their Thoughts quoting the National Institute on Aging, LBD is not normally considered a genetic disease, though family history raises risk (risk overview from For Their Thoughts).

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Which genes are linked to higher risk?

Several genes shape LBD susceptibility. An NIH-led genome-wide study found five genes — SNCA, APOE, BIN1, GBA and TMEM175 — affect LBD risk, linking LBD genetically to both Parkinson's and Alzheimer's disease, according to the National Institute on Aging news summary (NIH study summary from the National Institute on Aging. Most cases still have no known cause.

Family history can raise risk, and variants in APOE, SNCA and GBA are tied to higher risk without making LBD inherited in the usual sense. Rare variants act more strongly. Variants in SNCA and SNCB can cause dementia with Lewy bodies with autosomal-dominant inheritance, while GBA1 variants and one APOE e4 allele raise risk rather than causing the disorder directly.

What do those genes do in the brain?

The risk genes point to problems with protein buildup and cleanup. SNCA variants produce misshapen alpha-synuclein that clumps into Lewy bodies, while SNCB variants allow that buildup to continue. GBA1 variants disrupt lysosomes, the cell parts that break down waste.

APOE e4 impairs lipid-related clearance, another cleanup path. These paths help explain why risk overlaps with other diseases. Protein clumping resembles Parkinson's disease, while poor clearance resembles Alzheimer's disease.

Why can't a gene test diagnose LBD?

No genetic test can accurately predict whether someone will develop LBD, and genetic testing is not usually used to make the diagnosis. A person can carry a risk variant and never develop symptoms. Genetics only stratifies risk.

That limit matters because families may expect a clear yes-or-no answer from DNA. Clinical diagnosis rests on observed decline plus supporting signs. It uses progressive cognitive decline with core features and indicative biomarkers such as abnormal dopamine-transporter FP-CIT/DaTSCAN imaging, according to the Lewy Body Dementia Association (imaging guidance from the Lewy Body Dementia Association).

What should families do with genetic information?

Use genes as context for care, not as a diagnosis. Review family history of dementia, Parkinson's disease, and early thinking or movement changes with the doctor.

A normal result does not clear the issue. About 30% of DLB cases have normal FP-CIT scans, so doctors still weigh symptoms when scans and genes look normal. Keep follow-up visits when signs persist.

  • Write down parents, siblings, and age at first symptoms
  • Bring past DaTSCAN results, sleep-disorder notes, and drug reactions
  • Ask whether referral to counseling, neurology, or a memory clinic fits
  • Track new hallucinations, acting out dreams, stiffness, or falls

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.